Research programme: protein degrader cancer therapeutics - Guangzhou Lupeng Pharmaceuticals/Newave Pharmaceuticals
Latest Information Update: 12 Jul 2022
At a glance
- Originator Newave Pharmaceuticals
- Developer Guangzhou Lupeng Pharmaceutical; Newave Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 23 Jun 2022 Early research in Haematological malignancies in USA (unspecified route) (Guangzhou Lupeng Pharmaceutical pipeline; 20 June 2022)
- 23 Jun 2022 Early research in Solid tumours in USA (unspecified route) (Guangzhou Lupeng Pharmaceutical pipeline;20 June 2022)
- 22 Jun 2022 Early research in Haematological malignancies in China (unspecified route) (Guangzhou Lupeng Pharmaceutical pipeline; June 2022)